Increased activity of IGFBP7 (insulin-like growth factorbinding protein-7) is associated with cellular senescence, tissue aging, and obesity. IGFBP7 may be related to heart failure with preserved ejection fraction, a disease of elderly obese people.
H
eart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent diagnosis and is typically a disease of elderly, obese people. Many of the features of HFpEF, including changes in cardiomyocyte structure, endothelial function, collagen turnover, and vascular coupling, are also seen in the aging heart. In point of fact, several investigators have proposed HFpEF as a state of abnormal cardiovascular senescence, 1,2 though molecular mechanisms that contribute to this increasingly prevalent decline in cardiac structure and function remain poorly defined.
Tissue senescence results from permanent cell cycle arrest combined with loss of cellular homeostatic mechanisms maintaining tissue renewal. Recent studies have identified a pool of molecules secreted by senescent cells-the senescence-associated secretome-that exert autocrine, paracrine, and endocrine effects that collectively lead to cell cycle arrest. IGFBP7 (insulin-like growth factor-binding protein-7) is a 27 kD protein member of the senescence secretome. In states characterized by cell injury and abnormal growth, IGFBP7 acts to inhibit cell proliferation through G 1 phase cell cycle arrest, 3 reducing likelihood that maladaptive cellular derangements will be propagated. Notably, obesity is a contributor to senescence, and expression of IGFBP7 increases in parallel with increase in body mass index, 4 presumably as a compensatory mechanism.
Given association of IGFBP7 with aging and obesity, higher concentrations of IGFBP7 may therefore be involved in the development of HFpEF. Indeed, in previous small analyses, circulating concentrations of IGFBP7 are associated with cardiac hypertrophy, 5 abnormalities of ventricular filling dynamics, worse functional capacity, and poor prognosis in patients with HFpEF. [6] [7] [8] Interestingly, concentrations of neprilysin-an enzyme that has received recent attention for its role in HF pathophysiology and prognosis-are also implicated in aging and obesity. 9, 10 This potential link raises the possibility that inhibition of neprilysin might alter the activity of the senescence-associated secretome, and this modulation might be reflected in changes in circulating IGFBP7. To evaluate this possibility, we measured IGFBP7 concentrations in patients with available samples from the PARAMOUNT trial (Prospective Comparison of Angiotensin Receptor Blocker/Neprilysin Inhibitor With Angiotensin Receptor Blocker on Management of HFpEF Trial). 11 We hypothesized that concentrations of IGFBP7 would be associated with prevalent echocardiographic abnormalities typically seen in HFpEF, and neprilysin inhibition would lead to lower IGFBP7 concentrations.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results. All study procedures were approved by the Partners Healthcare Institutional Review Board.
Patient Population and Study Overview
The design and main results of PARAMOUNT (NCT00887588) have been previously published. 11 In brief, PARAMOUNT was a phase II, randomized, double-blind trial comparing effects of the angiotensin receptor blocker valsartan with sacubitril/ valsartan, a combination of an angiotensin receptor blocker with neprilysin inhibitor, in 301 subjects with New York Heart Association class I/-III HFpEF and NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration >400 pg/mL. Patients in the study had left ventricular ejection fraction (LVEF) ≥45%. The primary end point of PARAMOUNT was change in NT-proBNP concentrations from baseline to 12 weeks; treatment with sacubitril/valsartan led to 23% reduction in NT-proBNP compared with valsartan alone at this time point. In addition, after 36 weeks of treatment, left atrial (LA) width and LA volume index (LAVi) were significantly reduced from baseline to a greater extent by sacubitril/valsartan when compared with valsartan alone.
11
For the purposes of the present study, 228 study participants with available blood samples and echocardiographic images at baseline, 12 weeks, and 36 weeks were included. Table I in the Data Supplement details comparisons between those subjects from PARAMOUNT with and without IGFBP7; no important differences were found.
Imaging and Laboratory Evaluation
Sonographers at participating sites underwent training. Patients underwent detailed echocardiography at baseline,
WHAT IS NEW?
• In some cases, heart failure with preserved ejection fraction may represent a syndrome of accelerated tissue aging, affecting older, obese patients with metabolic abnormalities such as diabetes mellitus.
• We tested concentrations of a biomarker associated with tissue aging called IGFBP7 (insulinlike growth factor-binding protein-7) in patients with heart failure with preserved ejection fraction treated with either valsartan or sacubitril/ valsartan.
• We found IGFBP7 concentrations to be associated with diastolic dysfunction, and treatment with neprilysin inhibition lowered concentrations of IGFBP7.
WHAT ARE THE CLINICAL IMPLICATIONS?
• These results suggest a role of IGFBP7 in the development of diastolic abnormalities in heart failure with preserved ejection fraction, and may imply therapy with sacubitril/valsartan may attenuate this effect.
12 weeks, and 36 weeks; echocardiograms were sent on digital storage media to the echocardiography core laboratory at Brigham and Women's Hospital for analysis. Echocardiographic images, including 2-dimensional, Doppler, and tissue Doppler results, were interpreted blinded to clinical information and treatment assignment. Strain analyses were performed as previously reported. 12 The LA size was measured using biplane area-length methods using apical 4-and 2-chamber views at the end-systolic frame preceding mitral valve opening and was indexed to body surface area to derive LAVi. Early mitral inflow velocity (E wave) and peak late diastolic velocity (A wave) were measured by pulsed wave Doppler from the apical 4-chamber view with the sample volume positioned at the tip of the mitral leaflets. Annular diastolic velocity (E′) was obtained from the lateral and septal mitral annulus and averaged. Measures of diastolic dysfunction in this analysis include E/A and lateral E/E′ ratio; abnormal results for each are ≥1.5 and ≥15, respectively. 13 In addition, LAVi was considered as a consequence of diastolic dysfunction severity, with a result of ≥34 mL/m 2 considered threshold for abnormal. 13 At each study visit, blood samples were collected into serum separator tubes, processed, and frozen until the present analysis. IGFBP7 was measured using an Elecsys assay (Roche Diagnostics, Penzberg, Germany). The limit of detection for the IGFBP7 assay was 0.01 ng/mL. The interrun and intrarun coefficients of variation were ≤5% and ≤2%, respectively. Analysis of IGFBP7 was performed by Roche Diagnostics by laboratory personnel completely blinded to clinical information or treatment assignment.
Other biomarkers, including BNP, NT-proBNP, soluble (s) ST2, galectin-3, MMP (matrix metalloproteinase) 2, PIIINP (amino-terminal pro-peptide of type III collagen), and cyclic GMP, were measured as previously reported. 11, 14, 15 
Statistical Analyses
Whenever possible, analyses of IGFBP7 were done as a continuous variable; however, for display purposes, characteristics of study participants were summarized and compared across quartiles of baseline IGFBP7. Categorical variables were described using counts and percentages, normally distributed variables were expressed using means±SD, and non-normally distributed continuous variables (such as IGFBP7 concentrations) as medians [interquartile range]. Trends in baseline characteristics across IGFBP7 quartiles were assessed using Cochran-Armitage trend tests, linear regression, and Cuzick nonparametric trend test. 16 Concentrations of IGFBP7 were summarized and compared between patients with presence versus absence of diastolic dysfunction at baseline, 12, and 36 weeks, using the Wilcoxon rank-sum test. Spearman correlation was used to assess the relationship between continuous variables at baseline and log-transformed IGFBP7 concentrations; change in log-transformed IGFBP7 and change in echocardiographic parameters at 12 and 36 weeks were analyzed in the same manner. Multivariable linear regression analyses were performed to identify independent predictors of baseline LAVi; for these models, forward stepwise variable selection with threshold P=0.05 was used, with age and sex forced into the selection model. Effects of sacubitril/valsartan or valsartan on IGFBP7 concentration at 12 and 36 weeks were compared by examining median concentrations as well as absolute change of IGFBP7 as a function of treatment assignment at each time point. Overall treatment effect was also estimated as % change via a repeated-measures linear mixed-effects model using log-transformed IGFBP7 level, adjusted for baseline concentration. Correlations between change in IGFBP7 and either high sensitivity troponin T or NT-proBNP were analyzed using Spearman correlation. All P values are 2-sided with P<0.05 considered significant. No adjustments were made for multiple comparisons. Statistical analysis was conducted using STATA version 14 (Stata Corp, College Station, TX).
RESULTS
Figure I in the Data Supplement demonstrates a histogram of baseline IGFBP7 concentrations. Median IGFBP7 concentration at baseline regardless of treatment assignment was 191 ng/mL (164-225 ng/mL); at 12 and 36 weeks, the median values were 194 ng/ mL (169-234 ng/mL) and 185 ng/mL (163-220 ng/mL), respectively.
Baseline IGFBP7 Concentrations and Baseline Characteristics
Characteristics of the study subjects as a function of IGFBP7 quartiles are detailed in Table 1 , which demonstrates that higher IGFBP7 concentrations were associated with more advanced age, worse kidney function, and higher BNP and NT-proBNP concentrations. Notably, study participants with higher IGFBP7 concentrations were more likely to have larger baseline LA width and volume (both P<0.001), and modestly increased E/A (P=0.04) and E/E′ ratios (P=0.03). In contrast, no association between baseline IGFBP7 concentration and measures of LV size or systolic function was found.
In Spearman correlation, baseline IGFBP7 was weakly directly correlated E/E′ (ρ=0.16; P=0.03) and modestly correlated with LA width (ρ=0.28; P<0.001) and LAVi (ρ=0.27; P<0.001). Correlations between IGFBP7 and LVEF, LV size, or global longitudinal strain were nonsignificant (Table II in the Data Supplement) .
Besides moderate inverse correlation with estimated glomerular filtration rate, numerous other biomarkers were significantly correlated with IGFBP7, including BNP/NT-proBNP (Table II in the Data Supplement); concentrations of cyclic guanosine monophosphate were not correlated to IGFBP7, however. In contrast, baseline concentrations of biomarkers associated with fibrosis, including sST2, MMP2, galectin-3, and PIIINP, were all modestly correlated with baseline IGFBP7 (Figure 1 ).
IGFBP7 and Measures of Diastolic Dysfunction
Median concentrations of IGFBP7 at baseline were higher in those with E/A ≥1. BNP indicates B-type natriuretic peptide; E/A, early diastole/peak late diastolic velocity; E/E′, early mitral inflow velocity/annular diastolic velocity; eGFR, estimated glomerular filtration rate; HF, heart failure; IGFBP7, insulin-like growth factor-binding protein-7; LA, left atrium; LAVi, left atrial volume index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide); NYHA, New York Heart Association; and Q, quartile.
Study (Table IV in the Data Supplement). Though associations were present between IGFBP7 concentrations, and both E/A and E/E′, in adjusted models, concentrations of IGFBP7 did not independently predict either.
Predictors of LAVi in HFpEF
Using multivariable linear regression, independent predictors of LAVi were identified and detailed in Table 2 . Log-transformed IGFBP7 concentrations predicted LAVi (Z=2.56; P=0.01), regardless of other variables including prevalent atrial fibrillation, E/E′, or NT-proBNP. Given independent significance of IGFBP7 and NT-proBNP to predict LAVi, we then explored association between median LAVi as a function of baseline concentrations of each biomarker. To provide clinical context, in Figure 2 , when dichotomizing patients relative to median baseline IGFBP7 or NT-proBNP concentrations for the group as a whole, lowest median baseline LAVi was seen in those with both biomarkers below median, intermediate LAVi was seen in those with either marker elevated, while greatest median baseline LAVi was seen in those with both biomarkers elevated.
Treatment Assignment and IGFBP7 Concentrations
Concentrations of IGFBP7 at baseline, 12 weeks, and 36 weeks as a function of treatment with valsartan versus sacubitril/valsartan are detailed in Table 3 .
As expected, no statistically significant betweentreatment difference in median IGFBP7 values was seen at randomization. However, after 12 weeks, in a repeated-measures linear mixed-effects model median concentrations of IGFBP7 were lower in the patients treated with sacubitril/valsartan, when compared with valsartan. Median absolute change in IGFBP7 at 12 weeks was +15 ng/mL (−3 to +36 ng/mL) for those treated with valsartan versus −2 ng/mL (−13 to +14 ng/mL) for those treated with sacubitril/valsartan (P<0.001); the between-group difference at 12 weeks of −17 ng/mL (−25 to −10 ng/mL) was highly significant (P<0.001). By 36 weeks, though IGFBP7 had decreased further in the sacubitril/valsartan arm, differences between the 2 groups had waned as concentrations of IGFBP7 had dropped somewhat in the valsartan arm; absolute between-group difference in change from baseline was now −9 ng/mL (−18 to +0 ng/mL; P=0.06). A repeated-measures analysis of all postbaseline IGFBP7 values, adjusted for baseline IGFBP7, demonstrated a reduction of 7% with sacubitril/valsartan 
DISCUSSION
Among patients with HFpEF randomized to receive either valsartan or sacubitril/valsartan in the PARA-MOUNT study, we found concentrations of the senescence biomarker IGFBP7 to be associated with prevalent abnormalities of diastolic function and to predict presence of LA dilation, a potent predictor of HFpEF presence and severity. Notably, treatment with sacubitril resulted in a reduction in IGFBP7 concentrations, suggesting a possible intersection between neprilysin activity and tissue senescence.
Substantial attention has been given to pathways of tissue aging potentially playing an important role in development, exacerbation, and prognosis in HFpEF 1 : the diagnosis is typically observed in older, obese patients, and normal cardiac aging is associated with structural and functional changes typical of HFpEF, including cardiomyocyte hypertrophy and apoptosis, reduced responsiveness to β-adrenergic stimuli or decreased calcium sequestration, as well as increased extracellular collagen deposition; these changes may collectively contribute to increased cardiac stiffness in HFpEF. In experimental models, when occurring in the heart, the senescence-associated secretory phenotype may result in myocardial and vascular changes typical of HFpEF, including myocardial fibrosis and noncompliance. In this regard, some have argued that the clinical syndrome of HFpEF represents a state of abnormal myocardial aging. 17 To clarify pathways involved in the development of HFpEF, research has focused on measurement of circulating biomarkers to help understand the diagnosis 18, 19 and recent attention has focused on the cell cycle arrest biomarker IGFBP7 as a candidate for profiling the myocardial changes that occur in HFpEF: in theory, while arresting cellular cycling in the context of tissue injury may be favorable, 20 when excessive or persistent cell cycle arrest is present, a maladaptive phenotype may result, marked by excessive replacement fibrosis consequent to expression of numerous other growth factors, cytokines and proteases. 21 Indeed, experimentally, IGFBP7 exposure results in premature tissue aging and fibrosis. 22 Previously, in small studies of patients with HFpEF, we documented higher IGFBP7 concentrations associated with echocardiographic findings typical of HFpEF, higher estimated pulmonary artery pressures, and lower aortic capacitance 7 ; concentrations of IGFBP7 also appeared to be prognostic for death or hospitalization for HF as well. 8 We therefore wished to extend these observations; in a cohort of patients with symptomatic HFpEF and elevated NT-proBNP concentrations, we found higher concentrations of IGFBP7 associated with echocardiographic findings typical of HFpEF along with correlation with members of the cardiovascular inflammasome (such as ST2 and galectin-3) as well as biomarkers indicative of collagen turnover. Notably, IGFBP7 concentrations were not associated with measures of LV size or systolic function. Importantly, inhibition of neprilysin (through treatment with sacubitril/valsartan) resulted in lower concentrations of IGFBP7. Our results suggest that inhibition of neprilysin might modulate the senescence-associated secretory phenotype, reflected in reduction of IGFBP7 concentrations. More data are needed to verify or refute our findings.
Increased LA size and volume was strongly associated with IGFBP7 in the present study. This may be in part related to more prevalent atrial fibrillation in subjects with higher IGFBP7. However, in atrial tissue extracts of patients with atrial fibrillation, cardiac fibroblast and atrial myocytes demonstrated upregulation of senescence-associated markers β-galactosidase, p21
Cip1/Waf1 and P16
INK4a , accompanied by substantial atrial fibrosis, implying tissue aging associated with atrial fibrillation. 23 Accordingly, it is challenging to know whether association between IGFBP7 and LAVi increase is causation or consequence. Regardless, abnormality of LA size and function has particular importance in HFpEF, tracking with its presence, severity, and prognosis. 24, 25 Until this study, the circulating biomarker with strongest association to LA size and volume has been the natriuretic peptides; in our study, IGFBP7 provided strong prediction of LAVi comparable (and additive) to NT-proBNP. As NT-proBNP and IGFBP7 appear to inform different pathophysiology, their combined use to better define cardiovascular phenotypes in HFpEF deserves further study.
One of the most striking findings in our study was that treatment with sacubitril/valsartan led to significant reduction in IGFBP7 concentrations, while no such reduction was seen in those treated with valsartan. These data are the first to show favorable impact of a therapy on IGFBP7 concentration. As neprilysin activity facilitates adipogenesis and obesity 10, 26 and may also play a role in cellular senescence, 9, 27 the parallel reduction in IGFBP7 concentration after angiotensin receptor blocker with neprilysin inhibitor treatment raises potential for previously unsuspected beneficial impact of neprilysin inhibition on the senescence-associated secretory phenotype. This reduction in IGFBP7 may be a direct effect of neprilysin inhibition on pathways involved in senescence, or as an indirect benefit from other favorable effects of sacubitril on the underlying disease process. More data to better understand a role played by neprilysin in tissue senescence are needed, but our results open up potential avenues for research.
Though our results are novel, our work has limitations. First, we performed numerous comparisons without correction for multiple testing; analyses such as this may not absolutely require such correction, given its exploratory nature. As well, though the biology of IGFBP7 may be consistent with a role in HFpEF, it remains only speculative if IGFBP7 plays a direct or indirect role in the complex biology determining myocardial fibrosis/ stiffness and consequent increased cardiac filling pressures that are the hallmark of the diagnosis; indeed, IGFBP7 is found in other tissues besides the heart, so it is important to better understand the importance of local versus systemic production of IGFBP7 relative to the findings demonstrated in HFpEF. We did not correct our P values for multiple comparisons; thus, some of the findings could be because of play of chance; however, though our findings extend understanding of the interplay between IGFBP7 and diastolic function, we concede that prior studies have indicated such associations, which make our observations likely to be true. With <600 patients in total previously studied, further evaluation of IGFBP7 as a biomarker of diastolic dysfunction is reasonable; additionally, we describe potential therapeutic impact of sacubitril/valsartan on IGFBP7 concentrations, something that may inform future studies.
In conclusion, among patients with symptomatic HFpEF randomized in the PARAMOUNT study, we confirm that IGFBP7 concentrations are associated with echocardiographic findings consistent with myocardial aging. Neprilysin inhibition lowered IGFBP7 concentrations; considering neprilysin inhibition resulted in reduced LA size in PARAMOUNT, 11 it is reasonable to hypothesize possibility of reduced myocardial senescence as part of the benefit of this novel therapy. The impact of sacubitril/valsartan on outcomes in HFpEF is currently under exploration in the prospective, ran- 
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